fda approves first oral glp-1 obesity drug august 21 2025 New Pill Foundayo (Orforglipron) Gets Approval for FDA Approves First ORAL GLP-1

All covariates were assessed at baseline (index date) and did not vary over time

Promising Outcomes for Heart and Kidney Health In a study led by Dr

Tirzepatide shows promising hepatic effects in ongoing MASLD trials, and semaglutide has demonstrated modest liver fat reduction, but neither approaches the retatrutide benchmark

Ways to saveregardless of your insurance status

Diabetes 69 , 354-OR (2020)

Potential advantages Generally simpler anatomy than gastric bypass No intestinal rerouting Strong option for many first-time bariatric surgery patients Can be a good fit for patients who want a restrictive/metabolic procedure Usually avoids the malabsorption component of bypass Important considerations May worsen or trigger acid reflux in some patients May not be the best option for severe GERD or Barretts esophagus Requires lifelong attention to portion size, protein, vitamins, and habits Some patients may need revision later if reflux or weight regain occurs Gastric Bypass Also called Roux-en-Y gastric bypass Gastric bypass creates a small stomach pouch and reroutes part of the small intestine